February 24, 2011

HELIX BIOPHARMA CORP. FILES EUROPEAN CLINICAL TRIAL APPLICATION FOR A PHASE I/II STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47 (PDF)

AURORA, Ontario, February 24, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has filed a clinical trial application (“CTA”) with the Central Register of Clinical Trials at the Polish Ministry of Health seeking approval to perform its planned Phase I/II clinical safety, tolerability and preliminary efficacy study of its lung cancer drug candidate L-DOS47.